Bicara Therapeutics Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Claire Mazumdar Clemon
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 116 Huntington Avenue Boston MA United States of America 02116
- IPO Date
- Sep 13, 2024
- CIK
- 0002023658
- Website
- bicara.com
- Similar Companies
- Business
- Bicara Therapeutics Inc. (Nasdaq:BCAX) is a clinical-stage biopharmaceutical company that develops bifunctional antibodies combining tumor-targeting precision with tumor microenvironment modulation for solid tumors; its lead product candidate is ficerafusp alfa (BCA101), a first-in-class EGFR/TGF-beta bifunctional antibody evaluated as monotherapy and in combination with pembrolizumab in Phase 1/2 trials for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), including HPV-negative HNSCC, squamous cell anal cancer (SCAC), and squamous non-small cell lung cancer (SqNSCLC); early-stage discovery projects target undisclosed solid tumors. The company, founded in 2018 and headquartered at 116 Huntington Avenue, Suite 703, Boston, Massachusetts, operates primarily in the United States with clinical trial sites in major cities including Houston, New York, Boston, Toronto, Pittsburgh, Charleston, Los Angeles, San Diego, Tampa, Cleveland, and Providence. Recent developments include its initial public offering in September 2024, raising approximately $362 million through the sale of 20.125 million shares at $18 per share on Nasdaq; U.S. FDA Breakthrough Therapy Designation in 2025 for ficerafusp alfa plus pembrolizumab as first-line treatment in PD-L1-positive, HPV-negative recurrent/metastatic HNSCC; advancement of the pivotal Phase 2/3 FORTIFI-HN01 trial and ongoing Phase 1b expansion cohorts with updated data presented at the 2025 ASCO Annual Meeting showing deep and durable responses; and a $400 million shelf registration with $150 million at-the-market offering filed in November 2025 to support ficerafusp alfa development, extending cash runway into the first half of 2029.
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High – Here’s Why
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High on Analyst Upgrade
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript